LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...
DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...
The American Heart Association/American Stroke Association has issued a new scientific statement on the rationale for the inclusion and exclusion criteria for intravenous alteplase (tissue plasminogen ...
PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...
Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...
An off-label clot-busting drug appears to work slightly better in treating stroke patients than an approved medication, a new review finds. The clot-buster tenecteplase is associated with a slightly ...
Recombinant human prourokinase is noninferior to alteplase for acute ischemic stroke outcomes and is associated with decreased rates of symptomatic intracranial hemorrhage and major bleeding, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results